- NASDAQ: CATB has surged by 28.22% on Wednesday, hitting a new 2020 high.
- Premarket trading indicates another double-digit rally for Catabasis Pharmaceuticals Inc.
- Some suspect a short-squeeze may be in play.
- Fundamental developments needed to provide a long-term move.
A leap of some 50% in a span of two days – an impressive feat for a stock that has no news to back the surge. What is going on with Catabasis Pharmaceuticals Inc (NASDAQ: CATB)?
One theory surrounding the leap is that short-sellers have given up on their positions, allowing the surge. Covering these positions triggered caused some buying, which was later seized by others who jumped on the bandwagon. Fear Of Missing Out (FOMO) has been one of 2020's main themes in stock markets.
Another speculation comes from rises in Catabasis' peers. Auris Medical Holding Ltd (NASDAQ: EARS), nearly quintupled earlier this week. The surge in EARS was prompted by a coronavirus-related announcement, giving it a genuine reason to rise. Are speculators looking for the next pharmaceutical wonder? Small pharmaceutical firms can jump rapidly on any announcement these days.
Zooming out of recent market moves, it would take a material announcement from the firm, such as on its Edasalonexent novel oral investigational drug for Duchenne muscular dystrophy or its CAT-5571 medication for cystic fibrosis and mycobacterium tuberculosis to make CATB a longer-term investment.
CATB stock price
NASDAQ: CATB has been on an uptrend since mid-November when it traded below $1.40. Shares of the Boston-based pharmaceutical company advanced gradually to just above $1.60 before surging to close at $2.09 on Monday, a 28.22% leap.
The rally is set to continue, with Thursday's pre-market session pointing to another jump of over 13% to $2.38. It is essential to note that trading volume has leaped in recent days, giving the increase a dose of credibility despite the lack of any material development.
More NIO Stock Price and Forecast: Extends collapse as Chinese EV makers drop, NKLA buy opportunity eyed
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
EUR/USD consolidates weekly gains above 1.1150
EUR/USD moves up and down in a narrow channel slightly above 1.1150 on Friday. In the absence of high-tier macroeconomic data releases, comments from central bank officials and the risk mood could drive the pair's action heading into the weekend.
GBP/USD stabilizes near 1.3300, looks to post strong weekly gains
GBP/USD trades modestly higher on the day near 1.3300, supported by the upbeat UK Retail Sales data for August. The pair remains on track to end the week, which featured Fed and BoE policy decisions, with strong gains.
Gold extends rally to new record-high above $2,610
Gold (XAU/USD) preserves its bullish momentum and trades at a new all-time high above $2,610 on Friday. Heightened expectations that global central banks will follow the Fed in easing policy and slashing rates lift XAU/USD.
Week ahead – SNB to cut again, RBA to stand pat, PCE inflation also on tap
SNB is expected to ease for third time; might cut by 50bps. RBA to hold rates but could turn less hawkish as CPI falls. After inaugural Fed cut, attention turns to PCE inflation.
Bank of Japan set to keep rates on hold after July’s hike shocked markets
The Bank of Japan is expected to keep its short-term interest rate target between 0.15% and 0.25% on Friday, following the conclusion of its two-day monetary policy review. The decision is set to be announced during the early Asian session.
Moneta Markets review 2024: All you need to know
VERIFIED In this review, the FXStreet team provides an independent and thorough analysis based on direct testing and real experiences with Moneta Markets – an excellent broker for novice to intermediate forex traders who want to broaden their knowledge base.